CB2 Insights (CNSX:CBII) is a predictive analytics, software, and services company operating in the medical cannabis space. CEO Prad Sekar is excited about the company’s launch on the CSE and believes it is another step in achieving the company’s mission of mainstreaming medical cannabis. Sekar sees cannabis becoming a hallmark medication. The company’s technology allows point-of-care data gathering, which will provide the next level of validation for medical cannabis. CB2 Insights operates in 12 states and has 60,000 patient interactions per year. CB2 Insights completed a $5 million non-brokered private placement prior to going public to continue its execution plan and for further acquisitions and consolidation.

************************

Check out our website:
https://midasletter.com

************************

SUBSCRIBE to our YouTube:
http://bit.ly/MidasLetterYoutube

SUBSCRIBE to our 2nd YouTube Channel - Midas Letter Clips:
https://bit.ly/2rtQzgy

SUBSCRIBE to our Newsletter:
http://bit.ly/MidasLetterNewsletter

Download Our Podcast on iTunes:
http://bit.ly/MidasLetterPodcast

************************

Follow Us on Twitter:
http://bit.ly/MidasLetterTwitter

Like Us on Instagram:
http://bit.ly/MidasLetterInsta

Like Us on Facebook:
http://bit.ly/MidasLetterFacebook

************************

#Cannabis
#WeedStocks
#MidasLetter